The global Cell and Gene Therapy Market is valued at $20.5 billion in 2024 and is projected to reach a value of $128.8 ...

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

Objectives Tendinopathy is a frequent clinical problem and represents an extraordinary health economic and socioeconomic burden with high unmet medical needs. Recent clinical evidence suggests ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal ...

BridgeBio possesses a medium revenue cyclicality rating, and its operating leverage has a low rating. We assess the company's balance sheet as weak due to management's dependence on debt issuance to ...

US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

The U.S. Food and Drug Administration approved Mirum Pharmaceuticals' genetic disorder drug on Friday, making it the first ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.